BeiCell Therapeutics specializes in the development of innovative cell therapies based on its proprietary Chemically induced Pluripotent Stem Cell (CiPSC) technology. This method involves the chemical reprogramming of human somatic cells into pluripotent stem cells that exhibit key characteristics of embryonic stem cells. Compared to traditional methods, such as the Yamanaka factors, CiPSC technology offers advantages in terms of safety, simplicity, and efficiency, making it a promising platform for generating pluripotent stem cells for therapeutic applications.

In addition to CiPSC technology, BeiCell Therapeutics also focuses on allogeneic or "off-the-shelf" immune cell therapies. These therapies involve extracting immune cells from healthy donors through various means, including peripheral blood and umbilical cord blood, followed by engineering and expansion of these cells before they are administered to patients. This approach aims to provide readily available and effective immune cell treatments, enhancing the potential for widespread application in regenerative medicine and cancer therapy.

China

BeiCell Therapeutics is a revolutionary cell therapy company stemming from Prof. Hongkui Deng's lab at Peking University, aiming to provide completely off-the-shelf cell therapy for cancer, autoimmune diseases treatment and regenerative medicine.

BeiCell Therapeutics

Company Details